Eli Lilly, Kumquat Biosciences Form Cancer Collaboration
July 29 2021 - 10:16AM
Dow Jones News
By Colin Kellaher
Eli Lilly & Co. Thursday said it formed an exclusive cancer
collaboration with Kumquat Biosciences that could be worth more
than $2 billion to the drug discovery and development startup.
Eli Lilly said it will work with Kumquat to discover, develop
and commercialize potential novel small molecules that stimulate
tumor-specific immune responses.
The Indianapolis drugmaker said Kumquat will use its small
molecule immuno-oncology platform to discover novel clinical
candidates, while Eli Lilly has the option to select a certain
number of candidates for further development and
commercialization.
Eli Lilly said Kumquat will receive an initial $70 million,
consisting of a cash upfront payment and an equity investment, and
can earn more than $2 billion in potential milestone payments,
along with royalties on sales.
Kumquat, launched in 2019, previously raised more than $100
million in funding from investors including Lilly Asia
Ventures.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 29, 2021 10:01 ET (14:01 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024